A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer
To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer. In this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m(2) and irinoteca...
Uloženo v:
| Vydáno v: | Annals of oncology Ročník 18; číslo 12; s. 2000 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.12.2007
|
| Témata: | |
| ISSN: | 1569-8041, 1569-8041 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer.
In this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m(2) and irinotecan 180 mg/m(2) biweekly, standard arm B received a biweekly simplified folinic acid (FA) and fluorouracil (FU), FA 200 mg/m(2) in a 2-h infusion and bolus injection of 5FU 400 mg/m(2) on day 1, then a two 400 mg/m(2) continuous infusion of FU on days 1 and 2 with either oxaliplatin 85 mg/m(2) (20 patients) or irinotecan 180 mg/m(2) (20 patients).
Twenty-one partial responses (52.5%, median duration 7.2 months) were observed with the IRINOX arm and two complete and 20 partial responses (55%, median duration 6.4 months) with arm B. Median progression-free and overall survival times were 8.4 and 19 months, respectively, in the IRINOX arm and 8.1 and 20.4 months in arm B. Main grade 3/4 toxic effects were, respectively, neutropenia 42.5% and 32.5%; febrile neutropenia 10% and 5%; diarrhea 32.5% and 7.5%; vomiting 10.0% and 5%; neurosensory toxicity 17.5% and 7.5%.
The IRINOX arm has a manageable toxicity and is active. |
|---|---|
| AbstractList | To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer.
In this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m(2) and irinotecan 180 mg/m(2) biweekly, standard arm B received a biweekly simplified folinic acid (FA) and fluorouracil (FU), FA 200 mg/m(2) in a 2-h infusion and bolus injection of 5FU 400 mg/m(2) on day 1, then a two 400 mg/m(2) continuous infusion of FU on days 1 and 2 with either oxaliplatin 85 mg/m(2) (20 patients) or irinotecan 180 mg/m(2) (20 patients).
Twenty-one partial responses (52.5%, median duration 7.2 months) were observed with the IRINOX arm and two complete and 20 partial responses (55%, median duration 6.4 months) with arm B. Median progression-free and overall survival times were 8.4 and 19 months, respectively, in the IRINOX arm and 8.1 and 20.4 months in arm B. Main grade 3/4 toxic effects were, respectively, neutropenia 42.5% and 32.5%; febrile neutropenia 10% and 5%; diarrhea 32.5% and 7.5%; vomiting 10.0% and 5%; neurosensory toxicity 17.5% and 7.5%.
The IRINOX arm has a manageable toxicity and is active. To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer.BACKGROUNDTo assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer.In this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m(2) and irinotecan 180 mg/m(2) biweekly, standard arm B received a biweekly simplified folinic acid (FA) and fluorouracil (FU), FA 200 mg/m(2) in a 2-h infusion and bolus injection of 5FU 400 mg/m(2) on day 1, then a two 400 mg/m(2) continuous infusion of FU on days 1 and 2 with either oxaliplatin 85 mg/m(2) (20 patients) or irinotecan 180 mg/m(2) (20 patients).PATIENTS AND METHODSIn this randomized phase II trial, 80 patients were treated: arm A (IRINOX) in 40 patients received at day 1 oxaliplatin 85 mg/m(2) and irinotecan 180 mg/m(2) biweekly, standard arm B received a biweekly simplified folinic acid (FA) and fluorouracil (FU), FA 200 mg/m(2) in a 2-h infusion and bolus injection of 5FU 400 mg/m(2) on day 1, then a two 400 mg/m(2) continuous infusion of FU on days 1 and 2 with either oxaliplatin 85 mg/m(2) (20 patients) or irinotecan 180 mg/m(2) (20 patients).Twenty-one partial responses (52.5%, median duration 7.2 months) were observed with the IRINOX arm and two complete and 20 partial responses (55%, median duration 6.4 months) with arm B. Median progression-free and overall survival times were 8.4 and 19 months, respectively, in the IRINOX arm and 8.1 and 20.4 months in arm B. Main grade 3/4 toxic effects were, respectively, neutropenia 42.5% and 32.5%; febrile neutropenia 10% and 5%; diarrhea 32.5% and 7.5%; vomiting 10.0% and 5%; neurosensory toxicity 17.5% and 7.5%.RESULTSTwenty-one partial responses (52.5%, median duration 7.2 months) were observed with the IRINOX arm and two complete and 20 partial responses (55%, median duration 6.4 months) with arm B. Median progression-free and overall survival times were 8.4 and 19 months, respectively, in the IRINOX arm and 8.1 and 20.4 months in arm B. Main grade 3/4 toxic effects were, respectively, neutropenia 42.5% and 32.5%; febrile neutropenia 10% and 5%; diarrhea 32.5% and 7.5%; vomiting 10.0% and 5%; neurosensory toxicity 17.5% and 7.5%.The IRINOX arm has a manageable toxicity and is active.CONCLUSIONThe IRINOX arm has a manageable toxicity and is active. |
| Author | Thézenas, S Montoto-Grillot, C Cany, L Bécouarn, Y Senesse, P Jacob, J H Cvitkovic, F Adenis, A Boucher, E Ychou, M |
| Author_xml | – sequence: 1 givenname: Y surname: Bécouarn fullname: Bécouarn, Y email: becouarn@bergonie.org organization: Department of Digestive Oncology, Institut Bergonié, Regional Cancer Center, Bordeaux, France. becouarn@bergonie.org – sequence: 2 givenname: P surname: Senesse fullname: Senesse, P – sequence: 3 givenname: S surname: Thézenas fullname: Thézenas, S – sequence: 4 givenname: E surname: Boucher fullname: Boucher, E – sequence: 5 givenname: A surname: Adenis fullname: Adenis, A – sequence: 6 givenname: L surname: Cany fullname: Cany, L – sequence: 7 givenname: J H surname: Jacob fullname: Jacob, J H – sequence: 8 givenname: F surname: Cvitkovic fullname: Cvitkovic, F – sequence: 9 givenname: C surname: Montoto-Grillot fullname: Montoto-Grillot, C – sequence: 10 givenname: M surname: Ychou fullname: Ychou, M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17785765$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUk1v1DAQDaiIfsCRK5oTagVLnd18mVuVsiXSqpUQRYjLamJPdo0SO9hO6fYf9Xf0j-ENrVj58MbPb97MaHwY7WmjKYrexOxjzPjsFHUgxGknu1nOn0cHcZrxScGSeG8n3o8OnfvFGMv4lL-M9uM8L9I8Sw-e_TwDi1qaTt2RhH6NjqCqwFuFLdANtgN6pVfgsCG_gSAFaholUGzANOEOdNuTVR1pHzLEmjrj12Sx34Cl1ZaHY2WVNp5EUL8Hc4ut6tut7QeovlaXVz9ORl__x4DzIUIrAW3n4HjxPYX59TRk7VgYC__5HbcTUBoaZZ2ftEoTdOQx-HklQJjWWBJjh6gF2U-AodYgxyFCv3CuVuS8uiG4sGbon-j5w718uLfBxGi4HAFbAkkOyjCxDSgJFoP3BKXZEhCey7HGq-hFg62j1494FF3PP38rv0wWVxdVebaYiIQXfoI8mcqmLgomsyKPszSZMZbXtWTpDDFwMkHkLJysSQrGJZeYpimr4zqP0zibHkXv_vn21vwewhTLTjlBbYuazOCWGWdZWDcPwrePwqHuSC77sDa0m-XTb5j-BfdZvyI |
| CitedBy_id | crossref_primary_10_1038_s41419_022_04649_4 crossref_primary_10_1016_j_soc_2009_09_013 crossref_primary_10_1186_1471_2407_9_218 crossref_primary_10_1016_j_ejca_2008_09_005 crossref_primary_10_1016_j_ejca_2010_09_022 crossref_primary_10_1016_j_clcc_2011_03_027 crossref_primary_10_1593_tlo_12268 crossref_primary_10_1002_pds_1488 crossref_primary_10_3390_cancers14102470 |
| ContentType | Journal Article |
| CorporateAuthor | Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer |
| CorporateAuthor_xml | – name: Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/annonc/mdm379 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1569-8041 |
| ExternalDocumentID | 17785765 |
| Genre | Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0U7 1TH 23M 2WC 4.4 482 53G 5GY 5VS 5WA 6J9 70D AAEDW AAGQS AAJKP AAJQQ AAKAS AAKUH AALRI AAMVS AAOGV AAPNW AAUQX AAXUO AAYWO ABEUO ABIXL ABJNI ABKDP ABLJU ABNGD ABNKS ABOCM ABQLI ABSMQ ABZBJ ACGFO ACGFS ACPQN ACPRK ACUKT ACUTO ACVFH ADBBV ADCNI ADEYI ADHKW ADHZD ADOCK ADRTK ADVLN ADYVW ADZCM ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AEUPX AEWNT AFETI AFIYH AFJKZ AFOFC AFPUW AFSHK AGCQF AGINJ AGKEF AGKRT AGQPQ AGSYK AHMBA AHXPO AIAGR AIGII AIJHB AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN APXCP AQKUS ASPBG ATTQO AVWKF AXUDD AZFZN BAWUL BAYMD BGNMA BHONS BTRTY BVRKM BZKNY C1A CAG CDBKE CGR CKLRP COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DL5 D~K E3Z EBS ECM EE~ EFKBS EIF EJD EX3 FDB FEDTE GJXCC GX1 H13 H5~ HVGLF HW0 HZ~ I09 IH2 IHE J21 KAQDR KDC KOM LAK M-Z M41 M4Y MBLQV MHKGH N9A NGC NOYVH NPM NTWIH NU0 NVLIB O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RNI ROL RPX RW1 RZC RZE RZF RZO SDH TCURE TEORI TR2 U2A W8F WOQ WOW X7H YAYTL YFH YKOAZ ZKX ZXP ~91 7X8 |
| ID | FETCH-LOGICAL-c498t-a942dfb880d68716543007bbd053aad68d4aa909096f4809d9da5550b1b715162 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000252775800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1569-8041 |
| IngestDate | Sun Nov 09 10:16:04 EST 2025 Mon Jul 21 06:06:38 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c498t-a942dfb880d68716543007bbd053aad68d4aa909096f4809d9da5550b1b715162 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://dx.doi.org/10.1093/annonc/mdm379 |
| PMID | 17785765 |
| PQID | 69067859 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_69067859 pubmed_primary_17785765 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-12-01 |
| PublicationDateYYYYMMDD | 2007-12-01 |
| PublicationDate_xml | – month: 12 year: 2007 text: 2007-12-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Annals of oncology |
| PublicationTitleAlternate | Ann Oncol |
| PublicationYear | 2007 |
| SSID | ssj0006929 |
| Score | 1.9291048 |
| Snippet | To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer.
In... To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2000 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - administration & dosage Camptothecin - analogs & derivatives Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Fluorouracil - administration & dosage Humans Irinotecan Neoplasm Metastasis Organoplatinum Compounds - administration & dosage Oxaliplatin |
| Title | A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17785765 https://www.proquest.com/docview/69067859 |
| Volume | 18 |
| WOSCitedRecordID | wos000252775800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtNAEF1aiqq-cL-U6zzw0AosnHjXm0VIqKqIiNSGClEU9SVa766LJWyntguEP-p39MeYWdtqnuABRUqUib3ZKLMzZ_ZyDmMvk8RhIiPqSyNcwFNhAsWlCEKuo8HARUa60ItNyOl0NJupozX2rj8LQ9sq-5joA7UtDc2RvyFCXTkS6v3iLCDNKFpb7QQ01tlGhECGfFrOrrjCY-U1yrBAUQGx7HQMm1jCk8RLWRis-fNI_gVb-hwzvvV_vbvNbnbYEvZaZ7jD1lxxl20edqvn966d7AFmJlvm2W9nYfENExhMJuCFO6Cn_S5Oodapa5aAl4IjhgltllCm-B5W9QAA_-68O7-1BBJ4QDvsZFVWEPUDXv0Kyl8I8xe03a54DZPPk-mn2a5vt_lZQj-LAbrKa9g5-CpgfDzEu1aaKCu4sq-0tgtZAWmG0DUgnAy5azSdjcoMEA03hXHqIbl09RY0eBZd-hHYX2gX1TDMg595683jywt7edGOCOj4wr87sK4GPweOr9bBASl7A5F6VQ7w433_HffZ8fjDl_2PQactERiuRk2gFR_aNMHoZWOqGQWPEC0licWgpDXaLNdahfiIUz4KlVVWC6zmkkEiESTFwwfsOvqQe8SAYz7RiHqFQXBpeaj5kHbvGCN0yp2S2-xF7zNzHLu0IKMLV57X895rttnD1u3mi5ZiZD6QaJexePzPe5-wLT_d7HfYPGUbKUYt94zdMD-arK6e-yGBz9Ojwz9NhBxu |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized+phase+II+trial+evaluating+safety+and+efficacy+of+an+experimental+chemotherapy+regimen+%28irinotecan+%2B+oxaliplatin%2C+IRINOX%29+and+two+standard+arms+%28LV5+FU2+%2B+irinotecan+or+LV5+FU2+%2B+oxaliplatin%29+in+first-line+metastatic+colorectal+cancer%3A+a+study+of+the+Digestive+Group+of+the+F%C3%A9d%C3%A9ration+Nationale+des+Centres+de+Lutte+Contre+le+Cancer&rft.jtitle=Annals+of+oncology&rft.au=B%C3%A9couarn%2C+Y&rft.au=Senesse%2C+P&rft.au=Th%C3%A9zenas%2C+S&rft.au=Boucher%2C+E&rft.date=2007-12-01&rft.issn=1569-8041&rft.eissn=1569-8041&rft.volume=18&rft.issue=12&rft.spage=2000&rft_id=info:doi/10.1093%2Fannonc%2Fmdm379&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1569-8041&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1569-8041&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1569-8041&client=summon |